EMA examines key Actelion med Uptravi following 5 patient deaths in France by Carly Helfand Tuesday, February 14, 2017 J&J is counting on new buy Actelion’s pulmonary arterial hypertension meds to provide a top-line boost. But one of them may have just hit a safety snag.
Can Adempas meet Bayer's growth expectations after a canceled trial? by Carly Helfand Tuesday, May 17, 2016 Bayer has long counted pulmonary arterial hypertension newcomer Adempas among its Big 5 growth products. But should it?
